JP2015519401A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519401A5
JP2015519401A5 JP2015517370A JP2015517370A JP2015519401A5 JP 2015519401 A5 JP2015519401 A5 JP 2015519401A5 JP 2015517370 A JP2015517370 A JP 2015517370A JP 2015517370 A JP2015517370 A JP 2015517370A JP 2015519401 A5 JP2015519401 A5 JP 2015519401A5
Authority
JP
Japan
Prior art keywords
amino
pyrimidin
carbonyl
pyrazolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015517370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519401A (ja
JP6189945B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/045266 external-priority patent/WO2013191965A1/en
Publication of JP2015519401A publication Critical patent/JP2015519401A/ja
Publication of JP2015519401A5 publication Critical patent/JP2015519401A5/ja
Application granted granted Critical
Publication of JP6189945B2 publication Critical patent/JP6189945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015517370A 2012-06-18 2013-06-11 癌および自己免疫疾患の治療に有用な可逆性共有結合ピロロ−またはピラゾロピリミジン Active JP6189945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661203P 2012-06-18 2012-06-18
US61/661,203 2012-06-18
PCT/US2013/045266 WO2013191965A1 (en) 2012-06-18 2013-06-11 Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases

Publications (3)

Publication Number Publication Date
JP2015519401A JP2015519401A (ja) 2015-07-09
JP2015519401A5 true JP2015519401A5 (OSRAM) 2016-08-04
JP6189945B2 JP6189945B2 (ja) 2017-08-30

Family

ID=48692669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517370A Active JP6189945B2 (ja) 2012-06-18 2013-06-11 癌および自己免疫疾患の治療に有用な可逆性共有結合ピロロ−またはピラゾロピリミジン

Country Status (11)

Country Link
US (1) US20160045503A1 (OSRAM)
EP (1) EP2861599B1 (OSRAM)
JP (1) JP6189945B2 (OSRAM)
KR (1) KR102150432B1 (OSRAM)
CN (1) CN104487441B (OSRAM)
AU (1) AU2013277582B2 (OSRAM)
CA (1) CA2874461C (OSRAM)
DK (1) DK2861599T3 (OSRAM)
ES (1) ES2776175T3 (OSRAM)
MX (1) MX368112B (OSRAM)
WO (1) WO2013191965A1 (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
EP2731612A4 (en) 2011-07-13 2015-04-08 Pharmacyclics Inc BRUTON TYROSINE KINASE HEMMER
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
EP2890691B1 (en) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
HK1211942A1 (en) 2012-09-10 2016-06-03 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
BR112015011171A2 (pt) 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MX372673B (es) 2014-02-21 2020-03-25 Principia Biopharma Inc Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
RU2016139697A (ru) 2014-03-12 2018-04-12 Новартис Аг Комбинация, содержащая ингибитор btk и ингибитор akt
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
EP3174539A4 (en) 2014-08-01 2017-12-13 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase
AU2015300798A1 (en) 2014-08-07 2017-02-02 Pharmacyclics Llc Novel formulations of a Bruton's tyrosine kinase inhibitor
WO2016079693A1 (en) * 2014-11-19 2016-05-26 Sun Pharmaceutical Industries Limited A process for the preparation of ibrutinib
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
PT3236953T (pt) * 2014-12-24 2021-01-29 Principia Biopharma Inc Dosagem específica de sítio de um inibidor de btk
WO2016105582A1 (en) * 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
WO2016154998A1 (zh) * 2015-04-03 2016-10-06 安润医药科技(苏州)有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
CN106146511A (zh) * 2015-04-03 2016-11-23 安润医药科技(苏州)有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
SI3303334T1 (sl) * 2015-06-03 2021-09-30 Principia Biopharma Inc. Zaviralci tirozin kinaz
MA42242A (fr) * 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
WO2017027883A1 (en) * 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
KR20180109842A (ko) 2015-09-16 2018-10-08 록쏘 온콜로지, 인코포레이티드 화합물
CN114591242B (zh) 2015-12-16 2025-01-07 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
TWI753892B (zh) 2016-03-28 2022-02-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
CN107383013B (zh) * 2016-05-16 2020-03-31 苏州信诺维医药科技有限公司 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
EA201892836A1 (ru) 2016-06-29 2019-07-31 Принсипиа Биофарма Инк. Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN110483521B (zh) * 2018-05-14 2022-06-07 杭州和正医药有限公司 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用
KR102300092B1 (ko) * 2018-11-05 2021-09-09 가톨릭대학교 산학협력단 pH 민감성 탄소 나노입자, 이의 제조방법 및 이를 이용한 약물전달
CN111454268B (zh) * 2019-01-18 2023-09-08 明慧医药(上海)有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
WO2020263822A1 (en) 2019-06-25 2020-12-30 San Diego State University Foundation Selective btk irreversible inhibitors
WO2021029467A1 (en) * 2019-08-14 2021-02-18 Sam Chun Dang Pharm. Co., Ltd. A solid dosage form for orally administration
CN110448557A (zh) * 2019-09-05 2019-11-15 黄筱茜 抗凝血药达比加群酯的新药用途
MX2022004427A (es) 2019-10-14 2022-07-12 Principia Biopharma Inc Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
MX2022008428A (es) 2020-01-08 2022-08-08 Principia Biopharma Inc Composiciones farmaceuticas topicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitrilo.
CN115348862A (zh) 2020-01-20 2022-11-15 建新公司 用于复发型多发性硬化症(rms)的治疗性酪氨酸激酶抑制剂
MX2022009009A (es) 2020-01-22 2022-08-15 Principia Biopharma Inc Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
US20230295167A1 (en) * 2020-10-05 2023-09-21 Dana-Farber Cancer Institute, Inc. Potent and selective inhibitors of her2
EP4247795A1 (en) 2020-11-18 2023-09-27 Deciphera Pharmaceuticals, LLC Gcn2 and perk kinase inhibitors and methods of use thereof
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
US20240139326A1 (en) * 2020-12-23 2024-05-02 Yeda Research And Development Co. Ltd. Methacrylamides protein binders and uses thereof
KR102806844B1 (ko) * 2022-06-03 2025-05-16 주식회사 서흥 장용성 경질캡슐의 제조를 위한 밴딩 용액과 이를 이용하여 제조한 장용성 경질캡슐
CA3258672A1 (en) * 2022-06-16 2023-12-21 Amphista Therapeutics Limited BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20130035325A1 (en) 2009-11-16 2013-02-07 The Regents Of The University Of California Kinase inhibitors
CA2836449C (en) * 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
SI2710005T1 (sl) * 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze

Similar Documents

Publication Publication Date Title
JP2015519401A5 (OSRAM)
ES3036330T3 (en) Imidazopyridazines as modulators of il-17
ES2759775T3 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis B
CN110511209B (zh) 可用作激酶抑制剂的吲哚甲酰胺化合物
CN108738320B (zh) 用于治疗心血管疾病的cGMP调节剂
EP3312182B1 (en) Brk inhibitory compound
JP6218260B2 (ja) Jak阻害剤としてのアミノピリミジニル化合物
CN105732636B (zh) 杂芳化合物及其在药物中的应用
ES2871524T3 (es) Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
ES2651843T3 (es) Derivados de pirazolopirrolidina y su uso en el tratamiento de enfermedades
ES2745819T3 (es) Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
US20140357636A1 (en) Treatment of Skeletal-Related Disorders
RU2017106742A (ru) Комбинированная терапия для лечения парамиксовируса
JP2012501312A5 (OSRAM)
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
KR20230159419A (ko) Tyk2 억제제 및 이의 용도
SI2892900T1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
SI3106463T1 (en) Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase
RS54761B1 (sr) Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi
JP2010500414A5 (OSRAM)
JP2014531449A5 (OSRAM)
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
JP2016537384A5 (OSRAM)
JP2016537384A (ja) ピロロピロロン誘導体およびbet阻害剤としてのその使用
CN114222741A (zh) 作为p2x3抑制剂的吡啶并嘧啶类衍生物